

[Go to Product page](#)

## Datasheet for ABIN987845 FGF19 Protein

### Overview

Quantity:	1 mg
Target:	FGF19
Origin:	Human
Source:	Escherichia coli (E. coli)
Biological Activity:	Active

### Product Details

Sequence:	MRPLAFSDAG PHVHYGWGDP IRLRHLYTSG PHGLSSCFLR IRADGVVDCA RGQSAHSLLE IKAVALRTVA IKGVHSVRYL CMGADGKMQG LLQYSEEDCA FEEEIRPDGY NVYRSEKHRL PVSLSAKQR QLYKNRGFLP LSHFLPMLPM VPEEPEDLRG HLESDMFSSP LETDSMDPFG LVTGLEAVRS PSFE
Characteristics:	Fully biologically active when compared to standard. The ED50 as determined by the dose-dependent stimulation of the proliferation of balb/c 3T3 cells is 100-150ng/ml, corresponding to a specific activity of $> 6.6 \times 10^3$ units/mg.
Purity:	$> 95$ % by SDS-PAGE and HPLC analyses.
Endotoxin Level:	Level Less than 1EU/ $\mu$ g of rHuFGF-19 as determined by LAL method

### Target Details

Target:	FGF19
Alternative Name:	Fibroblast Growth Factor-19 (FGF-19) ( <a href="#">FGF19 Products</a> )
Background:	Fibroblast growth factor 19 (FGF19) belongs to the large FGF family which has at least 23

## Target Details

members. All FGF family members are heparin binding growth factors with a core 120 amino acid (aa) FGF domain that allows for a common tertiary structure. FGFs are expressed during embryonic development and in restricted adult tissues. Four distinct but related classes of FGF receptors, FGF R1, 2, 3, and 4, exist. Unlike most FGFs which bind to and activate more than one FGF receptor, FGF19 is a specific ligand for FGF R4. Synonym: Fibroblast Growth Factor-19 (FGF-19), Human. Formulation: Lyophilized from a 0.2µm filtered concentrated solution in PBS, pH 7.4.

**Molecular Weight:** Approximately 21.8 kDa, a single non-glycosylated polypeptide chain containing 195 amino acids.

**Pathways:** [RTK Signaling](#), [Fc-epsilon Receptor Signaling Pathway](#), [EGFR Signaling Pathway](#), [Neurotrophin Signaling Pathway](#)

## Application Details

**Restrictions:** For Research Use only

## Handling

**Format:** Lyophilized

**Reconstitution:** We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/ml. Stock solutions should be apportioned into working aliquots and stored at < -20 °C. Further dilutions should be made in appropriate buffered solutions.

**Storage:** 4 °C